Canada_IPAP - Impacts of antibiotic usage reduction in farmed animals
Lead Research Organisation:
University of Bristol
Department Name: Cellular and Molecular Medicine
Abstract
Antibiotics are used to prevent and treat bacterial infections in humans and animals. Antibiotics are natural products of microbes and have been present in the environment in small amounts for millions of years. Some environmental bacteria have therefore had time to evolve resistance to these antibiotics. Once we started using antibiotics to treat infections, we set off a chain of events that has led to pre-evolved resistance moving from its environmental origins into bacteria that cause disease. This "mobile" resistance can spread through bacterial populations, leading to long-term consequences when these bacteria cause infections. One example is the CTX-M enzyme, which gives resistance to 3rd generation cephalosporin (3GC) antibiotics. CTX-M was discovered 30 years ago, but it is now found in bacteria causing about 5% of urinary tract and bloodstream infections in humans in the UK.
3GCs are used to treat infections in humans and animals. However, because they are considered Highest Priority Critically Important Antimicrobials for use in humans, their use in farm animals in the UK has now almost stopped. This is because the Red Tractor farm assurance scheme, which is followed by 95% of UK farms, introduced new regulations around antibiotic use in mid 2018. One aim is to reduce the number of 3GC resistant bacteria in farm animals, which might spread to humans and cause resistant infections.
Some antibiotics, in contrast, are used to treat infections in farmed animals but never in humans (in the UK). One example is spectinomycin, which has been extensively used to treat sheep in the UK for decades. There are no rules specifically preventing the use of "farmed animal specific" antibiotics like spectinomycin, but in many countries, there is a general downward trend in antibiotic usage in farming. Furthermore, since late 2021, spectinomycin has no longer been available in the UK for treatment of sheep because its manufacturers have withdrawn it from sale. This might be expected to reduce rates of spectinomycin resistance in the UK sheep flock. We also see spectinomycin - and other farmed animal specific antibiotic resistance - in bacteria causing human infections, suggesting that there is a flow of resistant bacteria from farmed animals to humans. Maybe this will now start to reduce?
Moves to reduce antibiotic usage in farming are ongoing in many countries. This project aims to build a partnership between UK (University of Bristol) researchers and those in Canada (Universities of Montreal, Guelph, Calgary and Prince Edward Island) who are experts in antibiotic use and resistance in farmed animals, and/or in humans. In Canada, there has been variation in regulatory and industry-led changes to antibiotic usage in farming at provincial level, but generally, a downward trajectory in usage started later than it did in the UK.
Our partnership will be built though a variety of activities, but predominantly by collaborative research aiming to understand whether antibiotic usage reduction in farming is driving down antibiotic resistance levels on farms, and also in human infections. To do this, we will take advantage of natural experiments in the UK and Canada that are uniquely possibly for us to undertake, become of our ongoing involvement in large-scale longitudinal farm antibiotic usage and resistance surveillance projects, and the fact that antibiotic usage is being reduced in both countries at different rates and in subtly different ways.
It is very difficult to validly demonstrate a significant association between antibiotic usage reduction in farming on antibiotic resistance in bacteria on farms, and even more difficult to show and effect on human populations. This is because of all the potential confounding factors occurring in parallel that might also be driving down resistance. The value of our partnership is that we can pool our cutting edge technical expertise and so make these analysis possible.
3GCs are used to treat infections in humans and animals. However, because they are considered Highest Priority Critically Important Antimicrobials for use in humans, their use in farm animals in the UK has now almost stopped. This is because the Red Tractor farm assurance scheme, which is followed by 95% of UK farms, introduced new regulations around antibiotic use in mid 2018. One aim is to reduce the number of 3GC resistant bacteria in farm animals, which might spread to humans and cause resistant infections.
Some antibiotics, in contrast, are used to treat infections in farmed animals but never in humans (in the UK). One example is spectinomycin, which has been extensively used to treat sheep in the UK for decades. There are no rules specifically preventing the use of "farmed animal specific" antibiotics like spectinomycin, but in many countries, there is a general downward trend in antibiotic usage in farming. Furthermore, since late 2021, spectinomycin has no longer been available in the UK for treatment of sheep because its manufacturers have withdrawn it from sale. This might be expected to reduce rates of spectinomycin resistance in the UK sheep flock. We also see spectinomycin - and other farmed animal specific antibiotic resistance - in bacteria causing human infections, suggesting that there is a flow of resistant bacteria from farmed animals to humans. Maybe this will now start to reduce?
Moves to reduce antibiotic usage in farming are ongoing in many countries. This project aims to build a partnership between UK (University of Bristol) researchers and those in Canada (Universities of Montreal, Guelph, Calgary and Prince Edward Island) who are experts in antibiotic use and resistance in farmed animals, and/or in humans. In Canada, there has been variation in regulatory and industry-led changes to antibiotic usage in farming at provincial level, but generally, a downward trajectory in usage started later than it did in the UK.
Our partnership will be built though a variety of activities, but predominantly by collaborative research aiming to understand whether antibiotic usage reduction in farming is driving down antibiotic resistance levels on farms, and also in human infections. To do this, we will take advantage of natural experiments in the UK and Canada that are uniquely possibly for us to undertake, become of our ongoing involvement in large-scale longitudinal farm antibiotic usage and resistance surveillance projects, and the fact that antibiotic usage is being reduced in both countries at different rates and in subtly different ways.
It is very difficult to validly demonstrate a significant association between antibiotic usage reduction in farming on antibiotic resistance in bacteria on farms, and even more difficult to show and effect on human populations. This is because of all the potential confounding factors occurring in parallel that might also be driving down resistance. The value of our partnership is that we can pool our cutting edge technical expertise and so make these analysis possible.
Technical Summary
In many countries, antibiotic usage is being reduced in farming. The objective is mainly to reduce selective pressures on farm, since it is known that humans ingest farm-animal origin bacteria in food, and through interaction with the environment; and it is known that colonising flora, most notably enteric bacteria such as Escherichia coli, can cause opportunistic extra-intestinal infections. In the UK, the use of highest priority critically important antimicrobials (e.g. 3rd generation cephalosporins and fluoroquinolones) was effectively stopped in cattle due to introduction of new regulations by the Red Tractor farm assurance scheme in June 2018. In sheep, spectinomycin use stopped in late 2021 because the only licenced product was discontinued from manufacture. It is important (and scientifically interesting) to find out if such antibiotic usage changes have a significant impact on antibiotic resistance levels in bacteria on farms, and on the prevalence of resistant infections in humans. Some have tried, but it is far easier said than done, mainly due to the intertwining of other farm management, human antibiotic usage and infection control practices going on at the same time, which confound these analyses. To unravel this, we need a partnership of epidemiologists, molecular modellers, bioinformaticians, and the comprehensive data sets uniquely available from longitudinal surveillance studies on farms and in human cohorts. In this project, we will build a sustainable partnership (and ECR network) of UK and Canadian researchers with internationally recognised excellence in these disciplines, and unique access to the required farm and human longitudinal surveillance studies and associated meta data. We will undertake six research projects to address the impact of antibiotic usage reduction (starting with those described above) on the prevalence and ecology of antibiotic resistance on farms and in humans. We will deliver impact through stakeholder engagement.
Organisations
- University of Bristol (Lead Research Organisation)
- McGill University Health Centre (Collaboration)
- University of Prince Edward Island (Collaboration)
- Prince Edward Island University (Project Partner)
- University of Calgary (Project Partner)
- Innovation for Agriculture (Project Partner)
- University of Guelph (Project Partner)
- University of Montreal (Project Partner)
Publications
Reding C
(2024)
Hound: a novel tool for automated mapping of genotype to phenotype in bacterial genomes assembled de novo.
in Briefings in bioinformatics
| Description | Arwain DGC Phase 3 |
| Amount | £2,000,000 (GBP) |
| Funding ID | C123/2024/2025 |
| Organisation | Government of Wales |
| Sector | Public |
| Country | United Kingdom |
| Start | 03/2025 |
| End | 03/2026 |
| Description | Collaboration with J Trenton McClure |
| Organisation | University of Prince Edward Island |
| Country | Canada |
| Sector | Academic/University |
| PI Contribution | We will be sequencing isolates provided by Prof McClure and training him in data analysis. |
| Collaborator Contribution | Prof McClure has taken a sabbatical to work with us on a project attempting to understand the influence of antibiotic usage reduction on farms on antibiotic resistance. Providing isolates from a Canadian national surveillance study and related meta data for sequencing. |
| Impact | None yet |
| Start Year | 2023 |
| Description | Collaboration with Todd Lee |
| Organisation | McGill University Health Centre |
| Country | Canada |
| Sector | Academic/University |
| PI Contribution | Provided expertise to support grant application looking at AMR and outcome prediction in patients |
| Collaborator Contribution | Provided access to data and samples from international clinical trials led in Canada for project proposal |
| Impact | None so far |
| Start Year | 2023 |
| Description | Participation in Microbiology Society Knocking out AMR event |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Avison participated in discussion groups organised by the Microbiology Society to workshop ideas about surveillance of AMR and antibiotic usage data nationally and internationally including data standards. 60 people attended from across the globe. |
| Year(s) Of Engagement Activity | 2024 |
| Description | Path Safe Meeting |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | Avison took part in a working party to discuss genomic Surveillance of AMR within the UK, which was attended by around 80 participants from across the UK. A draft set of strategy proposals was produced. |
| Year(s) Of Engagement Activity | 2023 |
| Description | Talk at Arwain DGC Annual Conference |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | Matthew Avison gave a talk about the potential impact of antibiotic resistant bacteria evolving on farms on resistant human infections to an audience of primarily veterinary surgeons and farmers. |
| Year(s) Of Engagement Activity | 2024 |
| Description | Talk at Kingston University |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | Avison gave a talk about establishing interdisciplinary research networks to around 75 academics at Kingston University using the AMR research networks he has led as exemplars. |
| Year(s) Of Engagement Activity | 2023 |
| Description | Talk at MRF National PhD Training programme conference |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Postgraduate students |
| Results and Impact | Avison gave 40 minute keynote at the MRF AMR National PhD Training Programme annual conference attended by 120 PhD students studying AMR from across the UK. The talk was about AMR as a One Health research challenge |
| Year(s) Of Engagement Activity | 2023 |
| Description | Talk at University of Bristol Open Day |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Public/other audiences |
| Results and Impact | Avison gave a talk about Antibiotic resistance research to a group of potential university applicants and their parents attending university open day |
| Year(s) Of Engagement Activity | 2024 |
| Description | Talk at Weston College |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Schools |
| Results and Impact | Avison gave a talk to A level students at Weston College about AMR research in his group, around 40 students attended |
| Year(s) Of Engagement Activity | 2023 |
| Description | Talk to RUMA independent Scientific Group |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Industry/Business |
| Results and Impact | Avison gave an online talk about the zoonotic potential of antibiotic resistant bacteria evolved on farms to the Responsible Use of Medicines in Agriculture Scientific Group. |
| Year(s) Of Engagement Activity | 2024 |
| Description | UK-Canada AMR research project meeting |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Avison arranged and ran a day of talks at the Shaw Centre Ottowa about AMR in farming and concerning greater links between UK and Canadian researchers in that field. 35 people attended from Canada and UK. |
| Year(s) Of Engagement Activity | 2023 |
